Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5

James L. Murray, Michael G. Rosenblum, Carl E. Plager, Thomas P. Haynie, Monroe F. Jahns, Howard J. Glenn, Lamk Lamki, Robert S. Benjamin, Nicholas Papadopoulos, Arthur W. Boddie, Evan M. Hersh, Robert E. Sobol, Richard M. Bartholomew, James M. Frincke, Gary S. David, Dennis J. Carlo, James L. Murray

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

A radiolabeled monoclonal antibody (96.5) reactive with an Mr97,000 antigen found on over 80% of melanoma cell lines and tissue extracts was examined for its ability to detect malignant melanoma metastases in vivo. For imaging purposes, it was conjugated with diethyltriaminepentaacetic acid and subsequently labeled with 111ln by chelation. Thirty-one patients with metastatic melanoma received single injections of monoclonal antibody 96.5 at concentrations ranging from 0.5 to 20 mg and at specific activities of 111ln ranging from 0.125 to 4 mCi/mg. Total-body scans were performed at various time intervals following administration. No serious side effects were observed. Of a total of 100 previously documented metastatic sites, 50 imaged for a specificity of 50%. The number of sites imaged increased significantly as the amount of antibody administered increased relative to the average radiation dose. Considerable background uptake of isotope was observed in blood pool and other organs with gradual acquisition of label in tumor sites by 48 to 72 h. Hence, tumor imaging of melanoma using111 In-labeled monoclonal antibody 96.5 appeared feasible, especially at antibody doses above 2 mg.

Original languageEnglish
Pages (from-to)2376-2381
Number of pages6
JournalCancer Research
Volume45
Issue number5
Publication statusPublished - May 1 1985

Fingerprint

Radioimmunodetection
Melanoma
Monoclonal Antibodies
Tissue Extracts
Antibodies
Cell Extracts
Isotopes
Neoplasms
Radiation
Neoplasm Metastasis
Antigens
Cell Line
Injections
Acids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Murray, J. L., Rosenblum, M. G., Plager, C. E., Haynie, T. P., Jahns, M. F., Glenn, H. J., ... Murray, J. L. (1985). Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5. Cancer Research, 45(5), 2376-2381.

Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5. / Murray, James L.; Rosenblum, Michael G.; Plager, Carl E.; Haynie, Thomas P.; Jahns, Monroe F.; Glenn, Howard J.; Lamki, Lamk; Benjamin, Robert S.; Papadopoulos, Nicholas; Boddie, Arthur W.; Hersh, Evan M.; Sobol, Robert E.; Bartholomew, Richard M.; Frincke, James M.; David, Gary S.; Carlo, Dennis J.; Murray, James L.

In: Cancer Research, Vol. 45, No. 5, 01.05.1985, p. 2376-2381.

Research output: Contribution to journalArticle

Murray, JL, Rosenblum, MG, Plager, CE, Haynie, TP, Jahns, MF, Glenn, HJ, Lamki, L, Benjamin, RS, Papadopoulos, N, Boddie, AW, Hersh, EM, Sobol, RE, Bartholomew, RM, Frincke, JM, David, GS, Carlo, DJ & Murray, JL 1985, 'Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5', Cancer Research, vol. 45, no. 5, pp. 2376-2381.
Murray JL, Rosenblum MG, Plager CE, Haynie TP, Jahns MF, Glenn HJ et al. Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5. Cancer Research. 1985 May 1;45(5):2376-2381.
Murray, James L. ; Rosenblum, Michael G. ; Plager, Carl E. ; Haynie, Thomas P. ; Jahns, Monroe F. ; Glenn, Howard J. ; Lamki, Lamk ; Benjamin, Robert S. ; Papadopoulos, Nicholas ; Boddie, Arthur W. ; Hersh, Evan M. ; Sobol, Robert E. ; Bartholomew, Richard M. ; Frincke, James M. ; David, Gary S. ; Carlo, Dennis J. ; Murray, James L. / Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5. In: Cancer Research. 1985 ; Vol. 45, No. 5. pp. 2376-2381.
@article{eff4ed17b03146a1aaa6aa25dd30ce86,
title = "Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5",
abstract = "A radiolabeled monoclonal antibody (96.5) reactive with an Mr97,000 antigen found on over 80{\%} of melanoma cell lines and tissue extracts was examined for its ability to detect malignant melanoma metastases in vivo. For imaging purposes, it was conjugated with diethyltriaminepentaacetic acid and subsequently labeled with 111ln by chelation. Thirty-one patients with metastatic melanoma received single injections of monoclonal antibody 96.5 at concentrations ranging from 0.5 to 20 mg and at specific activities of 111ln ranging from 0.125 to 4 mCi/mg. Total-body scans were performed at various time intervals following administration. No serious side effects were observed. Of a total of 100 previously documented metastatic sites, 50 imaged for a specificity of 50{\%}. The number of sites imaged increased significantly as the amount of antibody administered increased relative to the average radiation dose. Considerable background uptake of isotope was observed in blood pool and other organs with gradual acquisition of label in tumor sites by 48 to 72 h. Hence, tumor imaging of melanoma using111 In-labeled monoclonal antibody 96.5 appeared feasible, especially at antibody doses above 2 mg.",
author = "Murray, {James L.} and Rosenblum, {Michael G.} and Plager, {Carl E.} and Haynie, {Thomas P.} and Jahns, {Monroe F.} and Glenn, {Howard J.} and Lamk Lamki and Benjamin, {Robert S.} and Nicholas Papadopoulos and Boddie, {Arthur W.} and Hersh, {Evan M.} and Sobol, {Robert E.} and Bartholomew, {Richard M.} and Frincke, {James M.} and David, {Gary S.} and Carlo, {Dennis J.} and Murray, {James L.}",
year = "1985",
month = "5",
day = "1",
language = "English",
volume = "45",
pages = "2376--2381",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Radioimmunoimaging in Malignant Melanoma with 111ln-labeled Monoclonal Antibody 96.5

AU - Murray, James L.

AU - Rosenblum, Michael G.

AU - Plager, Carl E.

AU - Haynie, Thomas P.

AU - Jahns, Monroe F.

AU - Glenn, Howard J.

AU - Lamki, Lamk

AU - Benjamin, Robert S.

AU - Papadopoulos, Nicholas

AU - Boddie, Arthur W.

AU - Hersh, Evan M.

AU - Sobol, Robert E.

AU - Bartholomew, Richard M.

AU - Frincke, James M.

AU - David, Gary S.

AU - Carlo, Dennis J.

AU - Murray, James L.

PY - 1985/5/1

Y1 - 1985/5/1

N2 - A radiolabeled monoclonal antibody (96.5) reactive with an Mr97,000 antigen found on over 80% of melanoma cell lines and tissue extracts was examined for its ability to detect malignant melanoma metastases in vivo. For imaging purposes, it was conjugated with diethyltriaminepentaacetic acid and subsequently labeled with 111ln by chelation. Thirty-one patients with metastatic melanoma received single injections of monoclonal antibody 96.5 at concentrations ranging from 0.5 to 20 mg and at specific activities of 111ln ranging from 0.125 to 4 mCi/mg. Total-body scans were performed at various time intervals following administration. No serious side effects were observed. Of a total of 100 previously documented metastatic sites, 50 imaged for a specificity of 50%. The number of sites imaged increased significantly as the amount of antibody administered increased relative to the average radiation dose. Considerable background uptake of isotope was observed in blood pool and other organs with gradual acquisition of label in tumor sites by 48 to 72 h. Hence, tumor imaging of melanoma using111 In-labeled monoclonal antibody 96.5 appeared feasible, especially at antibody doses above 2 mg.

AB - A radiolabeled monoclonal antibody (96.5) reactive with an Mr97,000 antigen found on over 80% of melanoma cell lines and tissue extracts was examined for its ability to detect malignant melanoma metastases in vivo. For imaging purposes, it was conjugated with diethyltriaminepentaacetic acid and subsequently labeled with 111ln by chelation. Thirty-one patients with metastatic melanoma received single injections of monoclonal antibody 96.5 at concentrations ranging from 0.5 to 20 mg and at specific activities of 111ln ranging from 0.125 to 4 mCi/mg. Total-body scans were performed at various time intervals following administration. No serious side effects were observed. Of a total of 100 previously documented metastatic sites, 50 imaged for a specificity of 50%. The number of sites imaged increased significantly as the amount of antibody administered increased relative to the average radiation dose. Considerable background uptake of isotope was observed in blood pool and other organs with gradual acquisition of label in tumor sites by 48 to 72 h. Hence, tumor imaging of melanoma using111 In-labeled monoclonal antibody 96.5 appeared feasible, especially at antibody doses above 2 mg.

UR - http://www.scopus.com/inward/record.url?scp=0021857576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021857576&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 2376

EP - 2381

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -